The established association between inflammatory bowel disease and colorectal cancer underscores the importance of inflammation in colon cancer development. Based on evidence that hemostatic proteases are powerful modifiers of both inflammatory pathologies and tumor biology, gene-targeted mice carrying low levels of prothrombin were used to directly test the hypothesis that prothrombin contributes to tumor development in colitis-associated colon cancer (CAC). Remarkably, imposing a modest 50% reduction in circulating prothrombin in fII +/-mice, a level that carries no significant bleeding risk, dramatically decreased adenoma formation following an azoxymethane/dextran sodium sulfate challenge. Similar results were obtained with pharmacological inhibition of prothrombin expression or inhibition of thrombin proteolytic activity.
INTRODUCTION
Multiple studies have suggested that hemostatic factors in general, and the central hemostatic protease thrombin, are major determinants of tumor biology, particularly late stage processes such as metastasis (1) (2) (3) (4) . In addition to supporting tumor cell dissemination, thrombin has been suggested to play a role in tumor proliferation and stroma formation (5) . However, the contribution of thrombin to tumor growth appears to be perplexingly variable and seemingly context dependent, as the growth of multiple transplantable tumors has been shown to be unaffected in mice with specific deficits in prothrombin or mice lacking selected downstream thrombin targets (e.g., fibrinogen, platelet function, factor XIII) (1, 3, (6) (7) (8) (9) . Equally enigmatic is the precise contribution of thrombin and other hemostatic factors to early events leading to cancer development, including tumor cell initiation events and events driving tumor promotion.
Previous studies linking tissue factor expression by transformed cells to tumorigenesis infer a role for circulating hemostatic factors in these early events (10, 11) , but the role of hemostatic factors downstream of tissue factor in cancer development, if any, remains to be determined.
Drawing together the independent evidence that: i) cancer risk is linked to inflammatory processes (12) (13) (14) , ii) hemostatic factors control inflammatory events (15) (16) (17) , and iii) the malignant phenotype is linked to procoagulant functions (1) , an attractive hypothesis is that a major contribution of thrombin to initial tumor development would be most manifest in inflammation-driven cancers.
Chronic inflammation is a major risk factor for the development of multiple malignancies, including cancers of the lung, liver, prostate, pancreas and colon (18) . There is equally impressive evidence that thrombin and multiple thrombin substrates drive the inflammatory response in diverse experimental settings (e.g., bacterial infection, arthritis, neuroinflammatory disease) (15) (16) (17) (19) (20) (21) . However, the contribution of thrombin to inflammation-driven cancers, particularly early events involved in tumor development, has never been formally explored. A 4 prime example of the strong association between inflammation and cancer is colitis-associated colon cancer (CAC). Patients with inflammatory bowel disease (IBD) have a 10-to 20-fold increased risk of colon cancer (22) . Multiple indirect observations are compatible with the hypothesis that thrombin is a determinant of CAC pathogenesis. Patients with IBD or colon cancer have a significantly increased risk of thromboembolism (23, 24) . Elevated biomarkers of hemostatic system activation correlate with a poor response to therapy in colitis and a poor prognosis in colon cancer (25, 26) . Epidemiological studies suggesting that IBD is less common in patients with inherited bleeding disorders infer a role for hemostatic factors in IBD pathogenesis (27) . Conversely, other studies have shown a strong correlation between some prothrombotic mutations (e.g., homozygosity for factor V Leiden ) and increased colon cancer risk (28) . Studies of animal models of colitis and CAC also suggest that hemostatic system components actively contribute to these pathologies. The immunological blockade of tissue factor was shown to diminish colitis associated inflammation and mucosal damage in mice (29) .
Fibrin(ogen)-mediated engagement of the leukocyte integrin  M  2 has been shown to drive colitis pathology and support the development and growth of colitis-associated adenomas (30) .
While these studies support the view that thrombin contributes to CAC pathogenesis, a direct analysis of the potential contribution(s) of thrombin to CAC has never been done.
To directly test the hypothesis that prothrombin supports tumor formation in the setting of inflammation-driven colon cancer, comparative analyses of CAC were done in cohorts of control mice and mice with germline-or pharmacologically-induced quantitative deficits in prothrombin.
We report that a modest decrease in circulating prothrombin (just 50% of normal) dramatically diminished adenoma formation. Interestingly, prothrombin diminution had no obvious impact on the severity of the antecedent colitis. However, lowering circulating prothrombin levels either constitutively or just during the inflammatory phase of the disease prevented the development of aberrant crypt foci and subsequent adenoma formation. These studies suggest that thrombin plays a significant role in very early events involved in tumorigenesis, at least in the context of inflammation-driven carcinogenesis.
MATERIALS AND METHODS
Transgenic mice. Mice heterozygous for a prothrombin (F2) null allele (fII +/− ) have been previously described (31, 32) . All study group mice were 8-12 week old males that were C57BL/6-inbred at least 6 generations. Wildtype and fII +/− mice were generated within the same breeding colony and housed in identical conditions. Study protocols were approved by the Cincinnati Children's Hospital Institutional Animal Care and Use Committee in accordance with NIH guidelines.
Antisense oligonucleotide-mediated prothrombin depletion and hirudin treatment. Prothrombin synthesis was suppressed in wildtype C57BL/6 mice using a previously described 20-mer antisense oligonucleotide (ASO) "gapmer" (2) . Cohorts were injected subcutaneously with 5 mg/kg fII-specific ASO, or an equivalent amount of a control irrelevant oligonucleotide of similar chemistry with no significant homology in the mouse transcriptome. Hepatic prothrombin mRNA and plasma prothrombin activity was measured as previously described (31) . In separate experiments, 10 mg/kg once daily hirudin (Lepirudin; Baxter) or saline carrier was injected i.p.
as specified in the text.
Induction of colitis and colon cancer. CAC was induced as previously described using a single phosphorylated RelA/p65 and Iba1 were performed essentially as previously described (30, 34) .
Colitis severity was assessed histologically using a semiquantitative histopathological scoring system based on the following: edema (0-3), percent ulceration (0-4), percent crypt loss (0-4), and inflammatory cell infiltrate (0-3) (30, 34) . Colonic cytokine concentrations were determined using Luminex technology on a BioPlex analyzer (Bio-Rad, Hercules, CA) from flash frozen distal colons homogenized in PBS with a protease inhibitor cocktail (Sigma-Adlrich). Statistical analyses were generated using Graphpad Prism software. Unless otherwise indicated, data shown represent mean with SEM, and P values were generated with a Mann-Whitney U test.
RESULTS

Prothrombin supports adenoma development/outgrowth in CAC.
To test the hypothesis that prothrombin supports tumor development in inflammation-driven cancers, we explored the impact of imposing a simple two-fold diminution in circulating prothrombin on colonic adenoma development in mice with CAC. Cohorts of mice heterozygous for a prothrombin null allele (fII
and wild-type (WT) controls were challenged in parallel with AOM/DSS as previously described (29) . As expected, evaluation of colonic tissues collected 12 weeks after AOM injection revealed uniform development of adenomas in all WT mice, most with multiple adenomas (Fig.   1A ). In contrast, fII +/-mice developed significantly fewer colonic adenomas (Fig. 1A) . As a complementary approach to explore the role of prothrombin in CAC, hepatic prothrombin expression was pharmacologically reduced using a previously described, highly-selective murine prothrombin ASO "gapmer" (2) . Here, cohorts of WT mice received weekly s.c. injections of a prothrombin-specific ASO or an equivalent dose of a biologically irrelevant control 3D) . Analyses of local cytokines in colonic homogenates from prothrombin-specific ASO and control oligonucleotide treated mice following 7 days of DSS also showed no significant differences associated with lowering prothrombin levels to ~50% of normal (See Supplemental Material).
To determine if decreasing prothrombin levels affects the degree of mucosal damage and inflammatory cell infiltration associated with multicourse DSS exposure, we challenged WT and fII +/-mice with 2 courses of DSS analogous to that used to induce adenoma formation.
Paralleling observations detailed above, the qualitative degree of waxing and waning colonic bleeding and diarrhea, as well as weight loss following DSS challenge/withdrawal were similar between genotypes ( determine whether the impact of thrombin on adenoma development/outgrowth is formally dependent on the antecedent colitis, we explored whether a modest reduction in prothrombin expression would limit adenoma formation in an experimental setting not driven by overt inflammation. Here, we induced adenomas in fII +/− and WT mice in parallel using an established protocol consisting of 6 weekly doses of AOM without DSS exposure. Contrasting experiments where adenoma formation was dependent on DSS-induced colitis, the decrease in prothrombin expression conferred by the fII +/− genotype had no effect on the number of adenomas formed after multicourse AOM (Fig. 5A) . Collectively, these results suggest that although limiting prothrombin does not overtly alter initial tissue damage and secondary inflammatory cell infiltration in AOM/DSS-challenged mice, the contribution of prothrombin to adenoma formation appears to be dependent on an inflammatory microenvironment.
To better define when in the course of disease pathogenesis prothrombin sufficiency is vital to adenoma development in CAC, two experimental designs were employed whereby ASO- 
levels (data not shown). Similar results were obtained when AOM/DSS challenged mice were treated with a protein-level inhibitor of thrombin proteolytic activity during the antecedent DSSinduced colitis (days 7 through 35). Here, mice receiving daily i.p. injections of the highly specific, albeit short-lived, thrombin inhibitor, hirudin, during this early timeframe developed significantly fewer adenomas than saline vehicle treated mice challenged in parallel (Fig. 5B) .
Consistent with findings in mice with low prothrombin levels, daily hirudin treatment had no significant effect on the degree of colonic mucosal damage or inflammatory cell infiltration observed following 7 days of DSS exposure (Fig. 5C) In contrast to the significant diminution in adenoma formation observed when selectively limiting prothrombin expression or thrombin catalytic activity during the early effector phase characterized by epithelial damage and colitis, the same interventions later in disease pathogenesis had no significant impact on adenoma formation. Here, ASO-mediated suppression of circulating prothrombin to half-normal starting one week after the withdrawal of the second DSS course (i.e., day 42) and continuing until sacrifice (i.e., day 84) had no significant effect on adenoma formation (Fig. 5D) . Similarly, daily hirudin treatment initiated immediately after completion of the second DSS course (i.e., day 35) and continuing until sacrifice did not significantly affect adenoma formation (Fig. 5D ). Taken together, these results suggest that the decrease in colitis-induced adenomas observed in mice with diminished circulating prothrombin is due to a direct action of thrombin-mediated proteolysis that is most relevant during the inflammatory phase of the disease process. 
Supplemental Material) at this early time point were not significantly affected by diminished prothrombin levels, there were 4-fold fewer aberrant crypt foci (ACF) within colonic epithelium harvested from prothrombin ASO treated animals relative to control mice (Fig. 6A) . These foci exhibited complex glandular structure with tortuous, branched lumens. The epithelial cells in these lesions showed loss of polarity with mitotic figures and nuclear atypia, including vesicular chromatin and nucleoli (Fig. 6B) . In contrast, the mucosa of colons harvested from mice with an ASO-mediated decrease in prothrombin expression was generally normal in appearance with significantly fewer ACF (Fig. 6B) . However, the few abnormal lesions that were present in this cohort were histologically indistinguishable from those observed in colons harvested from mice with normal prothrombin levels (Fig. 6C) . A separate independent analysis of identical experimental design was completed with similar results.
Immunohistochemical staining of colonic tissue harvested from mice with normal and low prothrombin levels 1 week after withdrawal of the second DSS course revealed significant fibrin(ogen) deposition associated with ACF (Fig. 6B) . The ACF that were observed in mice with low prothrombin levels, although significantly fewer in number, exhibited fibrin(ogen) deposits comparable to those observed in ACF seen in control mice (Fig. 6B) . Fibrin(ogen) deposition was rarely observed in areas of normal appearing colonic tissue, which predominated in mice with low prothrombin levels. Comparisons of apoptotic cells in these same tissues performed using a cleaved caspase 3 antibody revealed a similar degree of cellular apoptosis in cohorts with normal and low prothrombin levels (data not shown). Apoptotic nuclei were noted in superficial epithelial cells in intact appearing crypts and occasionally in ACF, regardless of prothrombin ASO treatment. Immunohistochemical staining for the marker of cellular proliferation, PCNA, revealed strongly positive nuclear staining in epithelial cells in ACF ( prothrombin ASO treated animals were generally composed of epithelial cells strongly positive for nuclear PCNA and histologically similar to ACF observed in control mice (Fig. 6B) . The more normal appearing colonic mucosa had only a few PCNA positive cells localized in the base of the colonic crypts, a pattern consistent with normal and/or healing mucosa (Fig. 6B) .
Immunohistochemical staining for phosphorylated RelA/p65, a marker of NF-κB activation, revealed a similar degree of positive staining cells in ACF, regardless of prothrombin levels (data not shown). Cells staining positive for this marker were uncommon in normal-appearing crypts. However, detailed quantitation of phosphorylated RelA/p65 staining cells in intact, non-ACF epithelia was significantly greater in control mice relative to mice with low prothrombin levels ( Fig. 6C) , consistent with the view that thrombin-mediated events fundamentally alter colonic epithelial cell functions in this context.
DISCUSSION
These studies establish, for the first time, that thrombin can play a key role in the development of pre-cancerous lesions and subsequent tumor formation in the context of inflammation-driven colon cancer. Taken together with prior reports showing that pro/thrombin is critical to metastasis in vivo (1, 2, 4, 8, 37, 38) , these studies show that this central hemostatic protease can drive both tumorigenesis and tumor dissemination. A remarkable facet of these studies was the finding that even a very modest 50% reduction in circulating prothrombin, imposing no significant bleeding risk (31) , was sufficient to dramatically decrease tumor formation in CAC.
Thrombin-mediated proteolysis was important in driving adenoma formation during the early, initiating phase of mucosal inflammation-associated tumorigenesis, although a modest reduction in thrombin activity affected neither the overall severity of mucosal damage, nor the accumulation of inflammatory cells and associated cytokines following DSS challenge.
Nevertheless, these studies demonstrate that inflammatory processes underlie the mechanism linking thrombin and adenoma formation, as decreasing prothrombin levels had no effect on The finding that thrombin promotes tumorigenesis in CAC through mechanisms that appear to depend on antecedent inflammation raises the possibility that thrombin-mediated events alter inflammatory functions in ways that are important for tumorigenesis but do not significantly affect inflammatory cell accumulation or mucosal damage. The local elaboration of inflammatory products has been suggested to directly support the progression of CAC through several independent mechanisms. For example, the local release of cytokines and growth factors has been proposed to support the survival and proliferation of pre-malignant and transformed cells (12, 18, 35, 39, 40) . A separate attractive concept is that the local release of potentially mutagenic reactive oxygen and nitrogen species increases the risk of transforming mutations in epithelial cells (13) . A link between thrombin, inflammatory control mechanisms, and adenoma formation is consistent with a substantial body of prior work illustrating the biological importance thrombin and thrombin substrates (e.g., PARs, protein C, factor XIII, fibrinogen) play in other inflammatory pathologies (15-17, 20, 41) . These findings support a working hypothesis whereby diminished thrombin activity results in profound differences in adenoma formation by modifying specific leukocyte activities (e.g., ROS production, elaboration of proteases, production of key cytokines or other effector molecules) rather than overtly affecting colonic mucosal damage or inflammatory cell infiltration. The overall view that thrombin promotes the formation of a CAN-13-3276 changes following DSS challenge, including less mucosal damage and lower local levels of numerous inflammatory cytokines relative to mice expressing wild-type fibrinogen (30) . Therefore, fibrin(ogen)-mediated  M  2 engagement promotes early inflammatory events in colitis that are coupled to the later development of adenomas. Given the critical importance of fibrin(ogen) in tumorigenesis in the context of CAC, it is possible that even a very modest decrease in local fibrin polymer formation stemming from lowered prothrombin expression, one that would not necessarily be detectable by immunostaining, could limit events crucial for tumorigenesis in this setting. It is also possible that modestly decreasing prothrombin expression limits fibrin polymer formation during a narrow, but critically important time period in tumorigenesis in CAC that ultimately limits adenoma formation. Of course, the fact that our analyses of experimental colitis in mice with lowered prothrombin expression did not precisely phenocopy analyses in mice with alterations in fibrinogen also raises the possibility that thrombin promotes tumorigenesis in CAC through mechanisms independent of fibrin polymerization.
Another model compatible with the data showing that thrombin drives tumorigenesis in CAC is that thrombin-mediated signaling events within tumor cell precursors dependent on an inflammatory milieu support tumorigenesis, but these events do not fundamentally alter mucosal damage or inflammatory events. In this regard, signaling through the thrombin-activatable receptor, PAR-1, could directly influence cell-intrinsic properties important in early tumor development (5, 37) . Intestinal epithelial cells have been shown to upregulate PAR-1 expression during times of cellular stress, such as inflammatory colitis (46) . Previous studies have suggested that tumor cell-associated PAR-1 activation supports tumor cell proliferation and limits apoptosis (5, 37) . Studies showing that PAR-1 is dispensable for tumorigenesis in the context of oncogene-driven breast cancer in mice demonstrate that this thrombin receptor is not critically required for tumorigenesis (47) . However, the role of PAR-1 in tumorigenesis has not In summary, these studies clearly indicate that the role of thrombin in cancer pathogenesis is not limited to late events, such as metastasis. Thrombin can also strongly influence tumorigenesis in the context of inflammation-driven colon cancer. Given that inflammation has been strongly implicated in the development of multiple malignancies (e.g., cervical, lung, gastric, ovarian, and prostate cancers) (12) (13) (14) , it is possible that the importance of thrombin in tumor development is not limited to colon cancer. These studies also imply that therapies designed to limit prothrombin expression or thrombin function may represent attractive options for preventing colon cancer in high-risk individuals without bleeding risk. 
